JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

Inicio・Lista de Acciones・Lisata Therapeutics

L
Lisata Therapeutics

Cerrado

4.57 0.66

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.51

Máximo

4.67

Métricas clave
By Trading Economics
Empleados	26

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	11M 31M
Apertura anterior	3.91
Cierre anterior	4.57

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 ene 2026, 23:51 UTC

Ganancias

Correction to Samsung Fourth-Quarter Net Profit Article

28 ene 2026, 23:49 UTC

Acciones populares

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 ene 2026, 23:19 UTC

Ganancias

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 ene 2026, 22:43 UTC

Ganancias

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 ene 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 ene 2026, 23:30 UTC

Charlas de Mercado

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 ene 2026, 23:28 UTC

Ganancias

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 ene 2026, 23:26 UTC

Ganancias

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 ene 2026, 23:21 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 23:18 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:58 UTC

Ganancias

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:48 UTC

Charlas de Mercado

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 ene 2026, 22:45 UTC

Ganancias

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 ene 2026, 22:44 UTC

Ganancias

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 ene 2026, 22:43 UTC

Ganancias

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 ene 2026, 22:41 UTC

Ganancias

Acciones populares

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 ene 2026, 22:41 UTC

Charlas de Mercado

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 ene 2026, 22:41 UTC

Ganancias

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 ene 2026, 22:40 UTC

Ganancias

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 ene 2026, 22:39 UTC

Ganancias

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 ene 2026, 22:38 UTC

Ganancias

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 ene 2026, 22:37 UTC

Ganancias

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 ene 2026, 22:35 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 22:26 UTC

Charlas de Mercado

Ganancias

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Consenso

By TipRanks

Neutral

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Lisata Therapeutics Dist en los últimos 3 meses.

Finanzas

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.